Peripheral blood profiling of melanoma patients eligible for immunotherapy revealed that those with the LAG-3 immunotype had poorer outcomes following ICI treatment compared to patients with the LAG-3+− immunotype (median overall survival: 22.2 vs. 75.8 months, respectively; p = 0.031), irrespective of other immune biomarkers such as PD-1 and tumor mutational burden (TMB) (39). Here, PDCD1 is linked to melanoma.